What’s new

• Promoters converted warrants into 90 lakh equity shares at ₹16.98 each.
• Promoter holding increased to 58.93% from 26.6%.
• Company collected ₹11.46 crore as the balance subscription amount.

Why it matters

The conversion shows strong promoter commitment and drastically increases their control, reducing public float dilution. For a micro-cap with ₹842 crore market cap, the infusion of ₹15.28 crore (including earlier tranche) is about 1.8% of market cap, signalling confidence.

What we’re watching

• How Sudarshan Pharma deploys the ₹15.28 crore—working capital or capex.
• Impact on EPS given the 3.6% equity dilution from 90 lakh new shares.
• Any subsequent business announcements from the promoters.

The full read

Sudarshan Pharma Industries' promoters converted warrants into 90 lakh equity shares at ₹16.98 each, bringing in ₹11.46 crore as the final installment. Total proceeds reached about ₹15.28 crore. Promoter stake rose from 26.6% to 58.93%. Decisive control now. For a micro-cap pharma company with a ₹842 crore market cap, the ₹15.28 crore infusion (roughly 1.8% of market cap) is a meaningful capital injection that strengthens the balance sheet and demonstrates promoter commitment. The 3.6% equity dilution is manageable. It's a vote of confidence from those who know the business best.

Primary source: BSE · NSE